Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients
- 1 February 2002
- journal article
- research article
- Published by Elsevier BV in Diabetes Research and Clinical Practice
- Vol. 55 (2), 99-103
- https://doi.org/10.1016/s0168-8227(01)00286-8
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level.Diabetes Care, 2000
- Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.Diabetes Care, 2000
- Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.Diabetes Care, 2000
- Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.Diabetes Care, 2000
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complicationsDiabetic Medicine, 1998
- Effects of Voglibose on Glycemic Excursions, Insulin Secretion, and Insulin Sensitivity in Non-lnsulin-ireated NIDDM PatientsDiabetes Care, 1998
- Relationship Between Gastric Emptying and an α-Glucosidase Inhibitor Effect on Postprandial Hyperglycemia in NIDDM PatientsDiabetes Care, 1997
- Voglibose (AO-128) Is an Efficient α-Glucosidase Inhibitor and Mobilizes the Endogenous GLP-1 ReserveDigestion, 1995
- Effect of an intestinal disaccharidase inhibitor (AO-128) on obesity and diabetesThe American Journal of Clinical Nutrition, 1992